Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 58-65

  Cersosimo, Robert J ^a,b   Jacobson, Daniel R ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Veterans Affairs Boston Healthcare System ^*

Author keywords

Anemia; Chemotherapy; Darbepoetin; Epoetin

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COST CONTROL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASMS;

EID: 32344447935     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G042     Document Type: Article

References (27)

1. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
2. Package insert. Epogen (epoetin alfa). Thousand Oaks, CA: Amgen, July 1999.
3. Package insert. Procrit (epoetin alfa). Raritan, NJ: Ortho Biotech, November 2002.
4. Package insert. Aranesp (darbepoetin alfa). Thousand Oaks, CA: Amgen, July 2002.
5. Blayney DW, Spiridonidis H, Fesen MR, et al. Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: experience in a randomized, open-label study (abstract 3003). Proc Am Soc Clin Oncol 2003;22:747.
6. Vadhan-Raj S, Schreiber F, Thomas LC, et al. Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients (pts) undergoing chemotherapy (abstract 2942). Proc Am Soc Clin Oncol 2003;22:732.
7. Charu V, Belani CP, Gill AN, et al. Every-2-week dosing of darbepoetin in patients with anemia of cancer: interim analysis of a randomized, controlled study (abstract). J Support Oncol 2004;2(suppl 2):26-7.
8. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
9. Reardon T, Charu V, Saidman B, et al. A randomized study of darbepoetin alfa every 3 weeks for chemotherapy-induced anemia (abstract). J Support Oncol 2004;2(suppl 2):24-5.
10. Drug topics red book update. Montvale, NJ: Thomson PDR, May 2004.
11. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381-95.
12. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992;61:393-8.
13. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(suppl):3-10.
14. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes on patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34.
15. Demitri GD, Mris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
16. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
17. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-9.
18. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;21:4126-34.
19. Hedenus M, Glaspy J, Dewey C, O'Byrne J, Colowick A. Dose response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies (abstract 1255). Blood 2001;98(11 suppl):297-8.
20. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomised, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
21. Vanteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
22. Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia: results of combined analysis. Oncology 2002;16(suppl 11):31-6.
23. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76.
24. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312-20.
25. Reeves TJ, Wallace JF, Patton JF. Darbepoetin alfa is comparable to epoetin alfa for chemotherapy-induced anemia in clinical practice (abstract). J Support Oncol 2004;2(suppl 2):10-1.
26. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003;25:2781-96.
27. Moore K, Former B. The impact of medical visits on patients with cancer (abstract). J Support Oncol 2004;2(suppl 2):4-5.